Cytokinetics, Incorporated has started enrolling patients in their Phase IIb study of tirasemtiv (formerly CK-2017357) in people with ALS. The study, called BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), will be used to determine the tolerability, safety, and efficacy of tirasemtiv in people with ALS. Tirasemtiv works via a novel mechanism to reduce – and even prevent – muscle fatigue. The lead investigator in the study Dr. Jeremy M. Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, said “if successful, this novel mechanism therapy could improve the lives of many patients living with ALS.” The trial will enroll 400 people with ALS from over 70 centers located in the United States, Europe, and Canada.
Click here to read more.Share this: